Onconetix, Inc. Basic Shares Outstanding (Weighted Average)
Onconetix, Inc. (ONCO) reported Basic Shares Outstanding (Weighted Average) of 2.24 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-13
- Onconetix, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 2.24M shares, a 19654.87% increase year-over-year.
- Onconetix, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 628.53K shares, a 1370.07% increase year-over-year.
- Onconetix, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 1.57M shares, a 1457.08% increase year-over-year.
- Onconetix, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 1.41M shares, a 9046.62% increase year-over-year.
- Onconetix, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 937.69K shares, a 2802.98% increase from fiscal 2024.
- Onconetix, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 32.30K shares, a 92.45% decline from fiscal 2023.
- Onconetix, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 427.78K shares, a 96.51% decline from fiscal 2022.
- Onconetix, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 12.27M shares, a 283.48% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 3 month as first filed | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 6 month as first filed | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 9 month as first filed | Weighted Average Number of Shares Outstanding, Basic 12 month | Weighted Average Number of Shares Outstanding, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 2.24M shares 10-Q · filed 2026-08-13 | 1.16M shares 10-Q · filed 2026-08-13 | 1.48M shares derived: average of 3 quarters · filed 2026-08-13 | 1.46M shares derived: average of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | 628.53K shares 10-Q · filed 2026-05-13 | 1.10M shares derived: average of 2 quarters · filed 2026-05-13 | 1.20M shares derived: average of 3 quarters · filed 2026-05-13 | 903.45K shares derived: average of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | 1.57M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | 1.49M shares derived: average of 2 quarters · filed 2026-03-13 | 995.10K shares derived: average of 3 quarters · filed 2026-08-13 | 937.69K shares 10-K · filed 2026-03-13 | ||||
| 2025-09-30 | 1.41M shares 10-Q · filed 2025-11-13 | 708.41K shares derived: average of 2 quarters · filed 2026-08-13 | 727.43K shares 10-Q · filed 2025-11-13 | 390.08K shares derived: average of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | 11.35K shares 10-Q · filed 2026-08-13 | 567.65K shares 10-Q · filed 2025-08-14 | 7.84K shares 10-Q · filed 2026-08-13 | 392.13K shares 10-Q · filed 2025-08-14 | 51.61K shares derived: average of 3 quarters · filed 2026-08-13 | 42.55K shares derived: average of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | 42.76K shares 10-Q · filed 2026-05-13 | 18.18M shares 10-Q · filed 2025-06-12 | 71.74K shares derived: average of 2 quarters · filed 2026-05-13 | 52.95K shares derived: average of 3 quarters · filed 2026-05-13 | 41.34K shares derived: average of 4 quarters · filed 2026-05-13 | |||
| 2024-12-31 | 100.73K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | 58.05K shares derived: average of 2 quarters · filed 2026-03-13 | 40.88K shares derived: average of 3 quarters · filed 2026-03-13 | 32.30K shares 10-K · filed 2026-03-13 | 2.75M shares 10-K · filed 2025-06-02 | |||
| 2024-09-30 | 15.37K shares 10-Q · filed 2025-11-13 | 1.31M shares 10-Q · filed 2024-12-10 | 10.95K shares derived: average of 2 quarters · filed 2025-11-13 | 9.49K shares 10-Q · filed 2025-11-13 | 806.74K shares 10-Q · filed 2024-12-10 | 263.20K shares derived: average of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | 6.53K shares 10-Q · filed 2025-08-14 | 22.20M shares 10-Q · filed 2024-08-29 | 6.52K shares 10-Q · filed 2025-08-14 | 22.17M shares 10-Q · filed 2024-08-29 | 345.81K shares derived: average of 3 quarters · filed 2025-08-14 | 368.87K shares derived: average of 4 quarters · filed 2025-08-14 | ||
| 2024-03-31 | 553.69K shares 10-Q · filed 2025-06-12 | 22.15M shares 10-Q · filed 2024-05-20 | 515.46K shares derived: average of 2 quarters · filed 2025-06-12 | 489.65K shares derived: average of 3 quarters · filed 2025-06-12 | 4.34M shares derived: average of 4 quarters · filed 2025-06-12 | |||
| 2023-12-31 | 477.23K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-02 | 457.63K shares derived: average of 2 quarters · filed 2025-06-02 | 5.61M shares derived: average of 3 quarters · filed 2025-06-02 | 427.78K shares 10-K · filed 2025-06-02 | 17.11M shares 10-K · filed 2024-04-11 | |||
| 2023-09-30 | 438.04K shares 10-Q · filed 2024-12-10 | 17.52M shares 10-Q · filed 2023-11-17 | 8.17M shares derived: average of 2 quarters · filed 2024-12-10 | 411.30K shares 10-Q · filed 2024-12-10 | 16.45M shares 10-Q · filed 2023-11-17 | 12.12M shares derived: average of 4 quarters · filed 2024-12-10 | ||
| 2023-06-30 | 15.91M shares 10-Q · filed 2024-08-29 | 15.91M shares 10-Q · filed 2024-08-29 | 16.02M shares derived: average of 3 quarters · filed 2024-08-29 | 15.60M shares derived: average of 4 quarters · filed 2024-08-29 | ||||
| 2023-03-31 | 15.91M shares 10-Q · filed 2024-05-20 | 16.07M shares derived: average of 2 quarters · filed 2024-05-20 | 15.50M shares derived: average of 3 quarters · filed 2024-05-20 | 14.62M shares derived: average of 4 quarters · filed 2024-05-20 | ||||
| 2022-12-31 | 16.24M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-11 | 15.29M shares derived: average of 2 quarters · filed 2024-04-11 | 14.19M shares derived: average of 3 quarters · filed 2024-04-11 | 12.27M shares 10-K · filed 2024-04-11 | ||||
| 2022-09-30 | 14.34M shares 10-Q · filed 2023-11-17 | 13.17M shares derived: average of 2 quarters · filed 2023-11-17 | 10.95M shares 10-Q · filed 2023-11-17 | 8.97M shares derived: average of 4 quarters · filed 2023-11-17 | ||||
| 2022-06-30 | 12.00M shares 10-Q · filed 2023-10-20 | 9.23M shares 10-Q · filed 2023-10-20 | 7.18M shares derived: average of 3 quarters · filed 2023-10-20 | 6.18M shares derived: average of 4 quarters · filed 2023-10-20 | ||||
| 2022-03-31 | 6.34M shares 10-Q · filed 2023-05-12 | 4.77M shares derived: average of 2 quarters · filed 2023-05-12 | 4.25M shares derived: average of 3 quarters · filed 2023-05-12 | 3.98M shares derived: average of 4 quarters · filed 2023-05-12 | ||||
| 2021-12-31 | 3.20M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | 3.20M shares derived: average of 2 quarters · filed 2023-03-09 | 3.20M shares derived: average of 3 quarters · filed 2023-03-09 | 3.20M shares 10-K · filed 2023-03-09 | ||||
| 2021-09-30 | 3.20M shares 10-Q · filed 2022-11-14 | 3.20M shares derived: average of 2 quarters · filed 2022-11-14 | 3.20M shares 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | 3.20M shares 10-Q · filed 2022-08-15 | 3.20M shares 10-Q · filed 2022-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |